CS
SOPH icon

Credit Suisse’s SOPHiA GENETICS SOPH Stock Holding History

Credit Suisse’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$10.7M Buy
2,167,540
+133,821
+7% +$646K 0.01% 892
2023
Q4 		$9.58M Buy
2,033,719
+1,882
+0.1% +$7.04K 0.01% 947
2023
Q3 		$5.18M Buy
2,031,837
+99,282
+5% +$315K 0.01% 1251
2023
Q2 		$8.66M Sell
1,932,555
-18,068
-0.9% -$81.7K 0.01% 995
2023
Q1 		$9.69M Sell
1,950,623
-3,997
-0.2% -$12.9K 0.01% 953
2022
Q4 		$4.03M Buy
1,954,620
+105,097
+6% +$236K ﹤0.01% 1438
2022
Q3 		$4.86M Sell
1,849,523
-3,388
-0.2% -$11.9K 0.01% 1270
2022
Q2 		$6.71M Sell
1,852,911
-1,372
-0.1% -$6.96K 0.01% 1120
2022
Q1 		$14.3M Buy
1,854,283
+8,179
+0.4% +$91.9K 0.01% 890
2021
Q4 		$26M Sell
1,846,104
-36,244
-2% -$534K 0.01% 965
2021
Q3 		$33M Buy
+1,882,348
New +$33.1M 0.02% 827

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $308M AUM 27.87% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
BPCE
Bank Pictet & Cie (Europe) Frankfurt Am Main, Germany $5.12B AUM 27.39% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Credit Suisse's SOPH Position: Q1 2024 in Review

Credit Suisse increased its SOPHiA GENETICS (SOPH) stake by 6.6% in Q1 2024, buying an estimated $646K and bringing the position to 2,167,540 shares worth $10.7M. The position accounts for 0.01% of the portfolio, ranked #892.

Credit Suisse first reported a position in SOPH in Q3 2021 and has held it in 11 quarters since. The position peaked at $33M in Q3 2021. 32 funds tracked by Wall St. Rank hold SOPH as of Q1 2024.

  • Credit Suisse held 2,167,540 shares of SOPHiA GENETICS worth $10.7M as of Q1 2024.
  • Credit Suisse bought 133,821 SOPHiA GENETICS shares in Q1 2024, an estimated $646K.
  • SOPHiA GENETICS made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #892 holding.
  • Credit Suisse first reported a position in SOPHiA GENETICS in Q3 2021 and has held it in 11 quarters since.
  • Credit Suisse's SOPHiA GENETICS position peaked at $33M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.